Skip to main content

Table 1 Baseline patient and disease characteristics

From: Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care

 

Omalizumab study, N = 46 (unless otherwise stated)

Ciclosporin study, N = 72 (unless otherwise stated)

Sex

 Male

10 (22%)

11 (15%)

 Female

36 (78%)

61 (85%)

Age (years)

 <20

0

3 (4%)

 20–29

10 (22%)

12 (17%)

 30–39

6 (13%)

16 (22%)

 40–49

16 (35%)

28 (39%)

 50–59

8 (17%)

7 (10%)

 60–69

5 (11%)

4 (6%)

 70–79

1 (2%)

2 (3%)

 Mean (SD)

43.3 (13.1)

40.5 (12.8)

Weight (kg)

n = 21

n = 24

 Mean (SD)

85.3 (27.1)

78.8 (16.2)

Diagnosis

 CSU only

36 (78%)a

66 (92%)

 CSU + CIndU

10 (22%)a

6 (8%)

History of angioedema

 All patients

38 (83%)

50 (69%)

 CSU only

31 (86%)

45 (68%)

 CSU + CIndU

7 (70%)

5 (83%)

Co-morbidities (not mutually exclusive)

 None

13 (28%)

43 (60%)

 Allergic condition

9 (20%)

10 (14%)

 Hypertension

8 (17%)

6 (8%)

 Asthma

7 (15%)

0c

 Eczema

7 (15%)

0c

 Thyroid disorder

3 (7%)

2 (3%)

 Depression

5 (11%)

4 (6%)

 Anxiety

1 (2%)

4 (6%)

 Other

17 (37%)b

16 (22%)b

Time since first symptoms (years)

N = 42

N = 57

 <1

0

12 (21%)

 1 < 5

15 (36%)

25 (44%)

 5 < 10

16 (38%)

10 (18%)

 ≥10

11 (26%)

10 (18%)

 Not recorded

4

15

 Median (IQR)

7.2 (3.7–10.0)

3.2 (1.5–7.6)

Time since diagnosis (years)

N = 37

N = 51

 <0.5

0

31 (61%)

 0.5 < 1

6 (16%)

11 (22%)

 1 < 5

17 (46%)

9 (18%)

 5 < 10

12 (32%)

0

 ≥10

2 (5%)

0

 Not recorded

9

21

 Median (IQR)

3.8 (1.2–7.5) years

3.7 (2.3–9.1) months

Previous 2nd/3rd line CSU medications (not mutually exclusive)

 2nd line

  Montelukast

23 (50%)

19 (16%)

  Dapsone

12 (26%)

3 (4%)

  H2-antihistamine

10 (22%)

8 (11%)

  Sulphasalazine

7 (15%)

1 (1%)

  Hydroxychloroquine

8 (17%)

1 (1%)

 3rd line

  Ciclosporin

33 (72%)

–

  Omalizumab

–

0

  Methotrexate

17 (37%)

1 (1%)

  Azathioprine

15 (33%)

4 (6%)

  Mycophenolate mofetil

12 (26%)

2 (3%)

  Tacrolimus

2 (4%)

0

  Any 3rd line

39 (85%)

7 (10%)

 Others

  UVB light therapy

1 (2%)

0

  Rituximab

1 (2%)

0

  Cyclophosphamide

1 (2%)

0

  Colchicine

3 (7%)

0

  Antidepressant

12 (26%)

6 (8%)

  Corticosteroids in previous 12 months

29 (74%) (n = 39)

18 (29%) (n = 63)

CSU severity and QoL

 UAS7 Score

n = 27

 

  0

0

–

  1–6 (well controlled)

1 (4%)

–

  7–15 (mild disease)

2 (7%)

–

  16–27 (moderate disease)

10 (37%)

–

  28–42 (severe disease)

14 (52%)

–

  Mean (SD)

27.5 (10.4)

–

  Median (IQR)

29.0 (20.7–36.1)

–

 DLQI Score

n = 32

n = 20

  0–1 (disease no impact on QoL)

0

0

  2–5 (small impact)

3 (9%)

0

  6–10 (moderate impact)

1 (3%)

1 (5%)

  11–20 (large impact)

9 (28%)

13 (65%)

  21–30 (extremely large impact)

19 (59%)

6 (30%)

  Mean (SD)

19.5 (7.1)

17.4 (6.6)

  Median (IQR)

21.5 (15.0–24.0)

16.5 (12.0–22.0)

  1. Only data that were recorded in the notes are included so the totals for each field are different for most characteristics.
  2. aTwo patients showed features of urticarial vasculitis (UV) during their recorded medical history.
  3. bOther co-morbidities (not specified in the study DCF) in omalizumab study patients were: Diabetes, 3; Chronic fatigue, 2; Obesity, 2; PVD, 2; osteoporosis/osteopenia, 2; COPD, inflammatory bowel disease, adrenal insufficiency, cardiovascular disease, renal transplant, haemophilia, sarcoidosis, inflammatory arthritis (×1 each). Other co-morbidities (not specified in the study DCF) in ciclosporin study patients were: Diabetes, 4; Autoimmune disorder, 3; Cardiovascular disease, 2 and IBS, Ovarian cysts/fibroids, Cancer, COPD, Chronic fatigue syndrome, pancreatitis, mastitis, stroke/TIA, PE, gall stones, sinusitis and facial nerve palsy (×1 each).
  4. cPatients with asthma or eczema were excluded from the ciclosporin study.
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us